Combined inhibition of tumor necrosis factor (TNF) and vascular endothelial growth factor (VEGF) for the treatment of macular edema of various etiologies: a short-term pilot study.
作者信息
Arevalo J F, Serrano M A, Wu L
出版信息
Eye (Lond). 2013 Apr;27(4):569-71. doi: 10.1038/eye.2012.301. Epub 2013 Jan 18.
Abstract
摘要
相似文献
1
Combined inhibition of tumor necrosis factor (TNF) and vascular endothelial growth factor (VEGF) for the treatment of macular edema of various etiologies: a short-term pilot study.联合抑制肿瘤坏死因子（TNF）和血管内皮生长因子（VEGF）治疗各种病因的黄斑水肿：一项短期初步研究。
Eye (Lond). 2013 Apr;27(4):569-71. doi: 10.1038/eye.2012.301. Epub 2013 Jan 18.
2
Intravitreal tumor necrosis factor-alpha inhibitors for neovascular age-related macular degeneration suboptimally responsive to antivascular endothelial growth factor agents: a pilot study from the Pan American Collaborative Retina Study Group.玻璃体内肿瘤坏死因子-α抑制剂治疗对抗血管内皮生长因子药物反应不佳的新生血管性年龄相关性黄斑变性：来自泛美合作视网膜研究组的一项初步研究。
J Ocul Pharmacol Ther. 2013 Apr;29(3):366-71. doi: 10.1089/jop.2012.0203. Epub 2012 Dec 5.
3
Intravitreal fasudil combined with bevacizumab for persistent diabetic macular edema: a novel treatment.
JAMA Ophthalmol. 2013 Jul;131(7):923-4. doi: 10.1001/jamaophthalmol.2013.143.
4
intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan-American Collaborative Retina Study Group.玻璃体内肿瘤坏死因子抑制剂治疗难治性糖尿病黄斑水肿：来自泛美合作视网膜研究组的一项初步研究。
Retina. 2011 Feb;31(2):298-303. doi: 10.1097/IAE.0b013e3181eac7a6.
5
Intravitreal bevacizumab in refractory uveitic macular edema: one-year follow-up.玻璃体内注射贝伐单抗治疗难治性葡萄膜炎性黄斑水肿：一年随访
Eur J Ophthalmol. 2009 Jul-Aug;19(4):622-9. doi: 10.1177/112067210901900417.
6
Anti-vascular endothelial growth factor drug treatment of diabetic macular edema: the evolution continues.抗血管内皮生长因子药物治疗糖尿病性黄斑水肿：进展仍在继续。
Curr Diabetes Rev. 2012 Jul 1;8(4):237-46. doi: 10.2174/157339912800840488.
7
Diabetic macular oedema in 2011: what are the options for refractory cystic oedema?2011年糖尿病性黄斑水肿：难治性囊性水肿有哪些治疗选择？
Clin Exp Ophthalmol. 2011 Sep-Oct;39(7):595-7. doi: 10.1111/j.1442-9071.2011.02662.x.
8
Anti-VEGF (vascular endothelial growth factor) drugs in diabetic macular oedema.抗血管内皮生长因子（VEGF）药物治疗糖尿病性黄斑水肿
Eye (Lond). 2011 Feb;25(2):254; author reply 254. doi: 10.1038/eye.2010.182. Epub 2010 Dec 10.
9
Combined therapy with intravitreal bevacizumab and posterior subtenon triamcinolone acetonide injection in diabetic macular oedema.玻璃体腔内注射贝伐单抗联合后Tenon囊下注射曲安奈德治疗糖尿病性黄斑水肿
Acta Ophthalmol. 2014 Nov;92(7):e589-90. doi: 10.1111/aos.12420. Epub 2014 May 27.
10
Baseline choroidal thickness as a predictor for response to anti-vascular endothelial growth factor therapy in diabetic macular edema.基线脉络膜厚度作为糖尿病性黄斑水肿抗血管内皮生长因子治疗反应的预测指标
Am J Ophthalmol. 2015 Jan;159(1):85-91.e1-3. doi: 10.1016/j.ajo.2014.09.033. Epub 2014 Sep 28.
引用本文的文献
1
Incidence of diabetic retinopathy in anti-tnf treated rheumatic disease patients with type 2 diabetes.2 型糖尿病合并抗 TNF 治疗的风湿性疾病患者糖尿病视网膜病变的发生率。
Graefes Arch Clin Exp Ophthalmol. 2024 Nov;262(11):3559-3565. doi: 10.1007/s00417-024-06529-3. Epub 2024 Jun 6.
2
Sustained Inhibition of VEGF and TNF-α Achieves Multi-Ocular Protection and Prevents Formation of Blood Vessels after Severe Ocular Trauma.持续抑制血管内皮生长因子（VEGF）和肿瘤坏死因子-α（TNF-α）可实现多眼部保护并预防严重眼外伤后血管形成。
Pharmaceutics. 2023 Jul 31;15(8):2059. doi: 10.3390/pharmaceutics15082059.
3
A comprehensive review of intravitreal immunosuppressants and biologicals used in ophthalmology.眼科玻璃体内使用的免疫抑制剂和生物制剂的综合综述。
Ther Adv Ophthalmol. 2022 May 18;14:25158414221097418. doi: 10.1177/25158414221097418. eCollection 2022 Jan-Dec.
4
Insights into the pathogenesis of cystoid macular edema: leukostasis and related cytokines.黄斑囊样水肿发病机制的见解：白细胞淤滞及相关细胞因子
Int J Ophthalmol. 2019 Jul 18;12(7):1202-1208. doi: 10.18240/ijo.2019.07.23. eCollection 2019.
5
Blockade of Tumor Necrosis Factor-Alpha: A Role for Adalimumab in Neovascular Age-Related Macular Degeneration Refractory to Anti-Angiogenesis Therapy?肿瘤坏死因子-α的阻断：阿达木单抗在抗血管生成治疗难治的新生血管性年龄相关性黄斑变性中的作用？
Case Rep Ophthalmol. 2016 Mar 17;7(1):154-62. doi: 10.1159/000445102. eCollection 2016 Jan-Apr.
6
Update on intravitreal anti-tumor necrosis factor alpha therapies for ocular disorders.玻璃体内注射抗肿瘤坏死因子α治疗眼部疾病的最新进展。
J Ophthalmic Inflamm Infect. 2014 Oct 15;4:26. doi: 10.1186/s12348-014-0026-8. eCollection 2014.
本文引用的文献
1
intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan-American Collaborative Retina Study Group.玻璃体内肿瘤坏死因子抑制剂治疗难治性糖尿病黄斑水肿：来自泛美合作视网膜研究组的一项初步研究。
Retina. 2011 Feb;31(2):298-303. doi: 10.1097/IAE.0b013e3181eac7a6.
2
Intravitreal adalimumab for refractory uveitis-related macular edema.玻璃体内阿达木单抗治疗难治性葡萄膜炎相关黄斑水肿。
Ophthalmology. 2010 Aug;117(8):1612-6. doi: 10.1016/j.ophtha.2009.12.011. Epub 2010 Apr 8.
3
Regression of sight-threatening macular edema in type 2 diabetes following treatment with the anti-tumor necrosis factor monoclonal antibody infliximab.
Diabetes Care. 2005 Feb;28(2):445-7. doi: 10.2337/diacare.28.2.445.
Zotero 插件